US Stock Movement: LB Pharmaceuticals surged on October 15 — LB-102 data, buy rating, and phase III clinical trial

LB Pharmaceuticals October 15 Major Surge Analysis

Keywords: LB-102 data, Buy rating, Phase III clinical trial

1. On October 10, the company presented four posters related to LB-102 at the 39th European College of Neuropsychopharmacology Congress, covering projects such as bipolar depression, and the schizophrenia programs NOVA-2 and NOVA-3, and released preclinical data on its dual-mechanism of action.

2. On October 9, Canaccord Genuity initiated coverage of the company with a “Buy” rating and a target price of 65 USD; on October 6, Guggenheim also initiated with a “Buy” rating and a target price of 80 USD.

3. On October 6, the company announced it would hold an R&D Day on October 27 to introduce the mechanism of action of LB-102 and the schizophrenia Phase III project. Topline data for the NOVA-2 trial is expected to be released in the first half of 2027.

(Disclaimer: This content is generated by AI technology summarizing publicly available information for reference only and does not constitute investment advice.)